308 related articles for article (PubMed ID: 24714086)
1. Fatty acid elongation in non-alcoholic steatohepatitis and hepatocellular carcinoma.
Kessler SM; Simon Y; Gemperlein K; Gianmoena K; Cadenas C; Zimmer V; Pokorny J; Barghash A; Helms V; van Rooijen N; Bohle RM; Lammert F; Hengstler JG; Mueller R; Haybaeck J; Kiemer AK
Int J Mol Sci; 2014 Apr; 15(4):5762-73. PubMed ID: 24714086
[TBL] [Abstract][Full Text] [Related]
2. Hepatic lipid profile in mice fed a choline-deficient, low-methionine diet resembles human non-alcoholic fatty liver disease.
Haberl EM; Pohl R; Rein-Fischboeck L; Höring M; Krautbauer S; Liebisch G; Buechler C
Lipids Health Dis; 2020 Dec; 19(1):250. PubMed ID: 33298075
[TBL] [Abstract][Full Text] [Related]
3. Elevated free cholesterol in a p62 overexpression model of non-alcoholic steatohepatitis.
Simon Y; Kessler SM; Gemperlein K; Bohle RM; Müller R; Haybaeck J; Kiemer AK
World J Gastroenterol; 2014 Dec; 20(47):17839-50. PubMed ID: 25548482
[TBL] [Abstract][Full Text] [Related]
4. Hepatocellular carcinoma in a mouse model fed a choline-deficient, L-amino acid-defined, high-fat diet.
Ikawa-Yoshida A; Matsuo S; Kato A; Ohmori Y; Higashida A; Kaneko E; Matsumoto M
Int J Exp Pathol; 2017 Aug; 98(4):221-233. PubMed ID: 28895242
[TBL] [Abstract][Full Text] [Related]
5. Metabolic impact of partial hepatectomy in the non-alcoholic steatohepatitis animal model of methionine-choline deficient diet.
Carril E; Valdecantos MP; Lanzón B; Angulo S; Valverde ÁM; Godzien J; Rupérez FJ
J Pharm Biomed Anal; 2020 Jan; 178():112958. PubMed ID: 31718984
[TBL] [Abstract][Full Text] [Related]
6. Deletion of ELOVL6 blocks the synthesis of oleic acid but does not prevent the development of fatty liver or insulin resistance.
Moon YA; Ochoa CR; Mitsche MA; Hammer RE; Horton JD
J Lipid Res; 2014 Dec; 55(12):2597-605. PubMed ID: 25281760
[TBL] [Abstract][Full Text] [Related]
7. A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma.
Tucker RD; Ciofoaia V; Nadella S; Gay MD; Cao H; Huber M; Safronenka A; Shivapurkar N; Kallakury B; Kruger AJ; Kroemer AHK; Smith JP
Dig Dis Sci; 2020 Jan; 65(1):189-203. PubMed ID: 31297627
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of hepatic fatty acid compositions in patients with nonalcoholic steatohepatitis.
Yamada K; Mizukoshi E; Sunagozaka H; Arai K; Yamashita T; Takeshita Y; Misu H; Takamura T; Kitamura S; Zen Y; Nakanuma Y; Honda M; Kaneko S
Liver Int; 2015 Feb; 35(2):582-90. PubMed ID: 25219574
[TBL] [Abstract][Full Text] [Related]
9. Differential progression of unhealthy diet-induced hepatocellular carcinoma in obese and non-obese mice.
Hymel E; Vlock E; Fisher KW; Farazi PA
PLoS One; 2022; 17(8):e0272623. PubMed ID: 35994501
[TBL] [Abstract][Full Text] [Related]
10. Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis.
Morikawa R; Nakamoto N; Amiya T; Chu PS; Koda Y; Teratani T; Suzuki T; Kurebayashi Y; Ueno A; Taniki N; Miyamoto K; Yamaguchi A; Shiba S; Katayama T; Yoshida K; Takada Y; Ishihara R; Ebinuma H; Sakamoto M; Kanai T
J Hepatol; 2021 Mar; 74(3):511-521. PubMed ID: 33038434
[TBL] [Abstract][Full Text] [Related]
11. Chemerin in a Mouse Model of Non-alcoholic Steatohepatitis and Hepatocarcinogenesis.
Haberl EM; Pohl R; Rein-Fischboeck L; Feder S; Sinal CJ; Buechler C
Anticancer Res; 2018 May; 38(5):2649-2657. PubMed ID: 29715085
[TBL] [Abstract][Full Text] [Related]
12. Metabolism dysregulation induces a specific lipid signature of nonalcoholic steatohepatitis in patients.
Chiappini F; Coilly A; Kadar H; Gual P; Tran A; Desterke C; Samuel D; Duclos-Vallée JC; Touboul D; Bertrand-Michel J; Brunelle A; Guettier C; Le Naour F
Sci Rep; 2017 Apr; 7():46658. PubMed ID: 28436449
[TBL] [Abstract][Full Text] [Related]
13. Nonalcoholic steatohepatitis-associated hepatocarcinogenesis in mice fed a modified choline-deficient, methionine-lowered, L-amino acid-defined diet and the role of signal changes.
Suzuki-Kemuriyama N; Abe A; Nakane S; Yuki M; Miyajima K; Nakae D
PLoS One; 2023; 18(8):e0287657. PubMed ID: 37535625
[TBL] [Abstract][Full Text] [Related]
14. HILPDA promotes NASH-driven HCC development by restraining intracellular fatty acid flux in hypoxia.
Povero D; Chen Y; Johnson SM; McMahon CE; Pan M; Bao H; Petterson XT; Blake E; Lauer KP; O'Brien DR; Yu Y; Graham RP; Taner T; Han X; Razidlo GL; Liu J
J Hepatol; 2023 Aug; 79(2):378-393. PubMed ID: 37061197
[TBL] [Abstract][Full Text] [Related]
15. Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study.
Nakamura N; Hatano E; Iguchi K; Sato M; Kawaguchi H; Ohtsu I; Sakurai T; Aizawa N; Iijima H; Nishiguchi S; Tomono T; Okuda Y; Wada S; Seo S; Taura K; Uemoto S; Ikegawa M
BMC Cancer; 2019 Jun; 19(1):621. PubMed ID: 31238892
[TBL] [Abstract][Full Text] [Related]
16. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
Zoller H; Tilg H
Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
[TBL] [Abstract][Full Text] [Related]
17. Lipidomic and transcriptomic analysis of western diet-induced nonalcoholic steatohepatitis (NASH) in female Ldlr -/- mice.
Garcia-Jaramillo M; Spooner MH; Löhr CV; Wong CP; Zhang W; Jump DB
PLoS One; 2019; 14(4):e0214387. PubMed ID: 30943218
[TBL] [Abstract][Full Text] [Related]
18. Comparison of murine steatohepatitis models identifies a dietary intervention with robust fibrosis, ductular reaction, and rapid progression to cirrhosis and cancer.
Wei G; An P; Vaid KA; Nasser I; Huang P; Tan L; Zhao S; Schuppan D; Popov YV
Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G174-G188. PubMed ID: 31630534
[TBL] [Abstract][Full Text] [Related]
19. Activation of FXR modulates SOCS3/Jak2/STAT3 signaling axis in a NASH-dependent hepatocellular carcinoma animal model.
Attia YM; Tawfiq RA; Gibriel AA; Ali AA; Kassem DH; Hammam OA; Elmazar MM
Biochem Pharmacol; 2021 Apr; 186():114497. PubMed ID: 33675775
[TBL] [Abstract][Full Text] [Related]
20. Formononetin promotes fatty acid β-oxidation to treat non-alcoholic steatohepatitis through SIRT1/PGC-1α/PPARα pathway.
Liao J; Xie X; Wang N; Wang Y; Zhao J; Chen F; Qu F; Wen W; Miao J; Cui H
Phytomedicine; 2024 Feb; 124():155285. PubMed ID: 38185065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
